• Publications
  • Influence
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s
TLDR
Criteria for the symptomatic predementia phase of Alzheimer’s disease (AD), referred to in this article as mild cognitive impairment due to AD, has four levels of certainty, depending on the presence and nature of the biomarker findings.
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
TLDR
These new criteria are centred on a clinical core of early and significant episodic memory impairment and stipulate that there must also be at least one or more abnormal biomarkers among structural MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of amyloid beta or tau proteins.
Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory.
TLDR
A brief questionnaire form of the NPI (NPI-Q), intended for use in routine clinical practice, is developed and cross-validated in 60 Alzheimer's patients, providing a brief, reliable, informant-based assessment of neuropsychiatric symptoms and associated caregiver distress.
Practice parameter: Early detection of dementia: Mild cognitive impairment (an evidence-based review)
TLDR
Screening different groups of elderly individuals in a general or specialty practice would be beneficial in detecting dementia and persons with memory impairment who were not demented were characterized in the literature as having mild cognitive impairment.
Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study.
TLDR
These are the first population-based estimates for neuropsychiatric symptoms in MCI, indicating a high prevalence associated with this condition as well.
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
TLDR
It is proposed that downstream topographical biomarkers of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measurement and monitoring of the course of disease.
Revising the definition of Alzheimer's disease: a new lexicon
TLDR
This paper aims to advance the scientific discussion by providing broader diagnostic coverage of the AD clinical spectrum and by proposing a common lexicon as a point of reference for the clinical and research communities.
The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's
TLDR
Criteria for the symptomatic predementia phase of Alzheimer's disease (AD), referred to in this article as mild cognitive impairment due to AD, has four levels of certainty, depending on the presence and nature of the biomarker findings.
Practice parameter: Diagnosis of dementia (an evidence-based review)
TLDR
D diagnostic criteria for dementia have improved since the 1994 practice parameter, and further research is needed to improve clinical definitions of dementia and its subtypes, as well as to determine the utility of various instruments of neuroimaging, biomarkers, and genetic testing in increasing diagnostic accuracy.
Common variants in MS4A4/MS4A6E, CD2uAP, CD33, and EPHA1 are associated with late-onset Alzheimer’s disease
The Alzheimer Disease Genetics Consortium (ADGC) performed a genome-wide association study of late-onset Alzheimer disease using a three-stage design consisting of a discovery stage (stage 1) and two
...
1
2
3
4
5
...